These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21892694)

  • 1. Azathioprine induced hepatitis in patients with inflammatory bowel disease.
    Srirajaskanthan R; Valliani D
    Int J Clin Pharm; 2011 Oct; 33(5):724-5. PubMed ID: 21892694
    [No Abstract]   [Full Text] [Related]  

  • 2. Nodular regenerative hyperplasia of the liver secondary to azathioprine in a patient with inflammatory bowel disease.
    Bryant DL; Miles CJ; Gearry RB
    N Z Med J; 2010 Apr; 123(1313):74-6. PubMed ID: 20581898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M; Herrlinger K; Schaeffeler E; Stange EF
    Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
    [No Abstract]   [Full Text] [Related]  

  • 4. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity.
    McGovern DP; Travis SP; Duley J; Shobowale-Bakre el M; Dalton HR
    Gastroenterology; 2002 Mar; 122(3):838-9. PubMed ID: 11878296
    [No Abstract]   [Full Text] [Related]  

  • 5. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
    Griffiths AM
    Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing thiopurine therapy in inflammatory bowel disease.
    Chevaux JB; Peyrin-Biroulet L; Sparrow MP
    Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of AZA/6-MP treatment in children with IBD is necessary.
    Dubinsky MC
    Inflamm Bowel Dis; 2003 Nov; 9(6):386-8; discussion 392-3. PubMed ID: 14671488
    [No Abstract]   [Full Text] [Related]  

  • 8. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
    Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
    Corominas H; Díaz C; Vázquez G; Baiget M
    Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
    [No Abstract]   [Full Text] [Related]  

  • 10. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
    Campbell S; Kingstone K; Ghosh S
    Aliment Pharmacol Ther; 2002 Mar; 16(3):389-98. PubMed ID: 11876691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M; Theede K; Nielsen AM
    Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
    Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
    Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
    [No Abstract]   [Full Text] [Related]  

  • 15. Azathioprine-induced hypersensitivity hepatitis: tolerance to 6-mercaptopurine.
    Andrejic J; Rojas-Balcazar J; Dennis M; Berkelhammer C
    Inflamm Bowel Dis; 2010 Nov; 16(11):1828-9. PubMed ID: 20196148
    [No Abstract]   [Full Text] [Related]  

  • 16. Awareness of adverse effects of azathioprine in patients with inflammatory bowel disease--more to be done?
    Spence AD; Lee R; Keegan D; Doherty GA; Mulcahy H; Murphy S
    Ulster Med J; 2014 Jan; 83(1):56-7. PubMed ID: 24757277
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 18. What are the rules when treatment with 6-MP/AZA is started?
    Korelitz BI
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S262-3. PubMed ID: 18816727
    [No Abstract]   [Full Text] [Related]  

  • 19. Azathioprine induced nodular regenerative hyperplasia in IBD patients.
    Daniel F; Cadranel JF; Seksik P; Cazier A; Duong Van Huyen JP; Ziol M; Coutarel P; Loison P; Jian R; Marteau P
    Gastroenterol Clin Biol; 2005 May; 29(5):600-3. PubMed ID: 15980758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine induced serious portal hypertension: a case series of three IBD patients and review of the literature.
    Dooremont D; Decaestecker J; De Wulf D; Ghillebert G; Van Vlierberghe H; Van Dorpe J; Baert F
    Acta Gastroenterol Belg; 2013 Sep; 76(3):342-6. PubMed ID: 24261031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.